Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Neoplasms 314Carcinoma, Non-Small-Cell Lung 162Breast Neoplasms 125Neoplasm Metastasis 106Melanoma 95Leukemia, Myeloid, Acute 80Lymphoma 79Multiple Myeloma 74Colorectal Neoplasms 73Ovarian Neoplasms 70Lymphoma, Non-Hodgkin 63Recurrence 58Prostatic Neoplasms 56Pancreatic Neoplasms 51Lung Neoplasms 50Carcinoma, Renal Cell 40Glioblastoma 39Precursor Cell Lymphoblastic Leukemia-Lymphoma 38Lymphoma, Large B-Cell, Diffuse 37Leukemia, Lymphocytic, Chronic, B-Cell 37Advanced Solid Tumors 37Leukemia 36Myelodysplastic Syndromes 35Triple Negative Breast Neoplasms 34Head and Neck Neoplasms 33Sarcoma 31Brain Neoplasms 31Urinary Bladder Neoplasms 30Stomach Neoplasms 30Lymphoma, Follicular 28

Interventions

pembrolizumab 1pazopanib 1aldesleukin 1Sunitinib 1Nivolumab 1Ipilimumab 1Immunoglobulin G 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Has results × Clear-cell metastatic renal cell carcinoma × Clear all
NCT03260504 2025-12-08

Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer

University of Washington

Phase 1 Terminated
6 enrolled 11 charts
Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT01472081 2021-12-02

Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)

Bristol-Myers Squibb

Phase 1 Completed
194 enrolled 18 charts
Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡